Corcept posted second-quarter revenue of $256.1M, up 31.8% from the comparable prior-year period. The result splits between a mature Cushing's franchise and a freshly approved oncology asset. Korlym and the authorized generic generated $208.6M, while Lifyorli contributed $47.6M in its debut quarter. Management lifted full-year revenue guidance to $1.1B-$1.2B, embedding both the oncology launch curve and continued hypercortisolism prescription growth. Net income reached $43.0M against a year-ago level of $35.1M. The headline earnings power understates the underlying operating leverage, since the SG&A expansion reflects launch investment rather than structural deterioration. The forward setup combines a high-margin rare-disease franchise, a brand-new oncology indication, and a regulatory pathway with a December action date on the relacorilant Cushing's NDA.
The strategic question centers on how Corcept monetizes Lifyorli without sacrificing Cushing's economics. Launch uptake exceeded internal expectations, with more than 1,300 patients initiating therapy shortly after FDA approval in March. The oncology indication targets platinum-resistant ovarian cancer, a population with high unmet need and limited therapeutic alternatives. Korlym continues to set fresh quarterly prescription records as the CATALYST and MOMENTUM studies reshape physician awareness of hypercortisolism's prevalence. Patent litigation overhang remains the dominant equity risk. A February appellate ruling preserves Teva's ability to sell generic mifepristone. Settlements allow Hikma and Sun to enter subject to Teva availability. The balance between launch upside and generic erosion frames the bull-bear debate. Equity capitalization sits near $12.2B at a recent price above $112. The valuation premium reflects pipeline option value rather than current earnings power.
The combination of cash flow self-sufficiency, a fresh commercial launch, and a binary regulatory catalyst makes Corcept a setup-driven name rather than a steady compounder. Cushing's franchise economics remain the foundation, with Korlym and the authorized generic delivering predictable high-margin revenue against a stable patient population. Lifyorli adds a second growth vector that did not exist a year ago. The relacorilant NDA in Cushing's could unlock a label-friendly alternative to Korlym and recapture share lost to Teva's authorized generic. Execution against the December action date, plus visible oncology ramp, defines the next twelve months.